Conjugated sodium tyropanoate (Bilopaque) in the bowel: significance of its presence or absence after first-dose oral cholecystography.
Oral cholecystography following the ingestion of 4.5 g of sodium tyropanoate (Bilopaque) was performed in 1,053 patients. The radiographs of 89 patients in whom the gallbladder was either faintly visualized or nonvisualized were reviewed for the presence of conjugated contrast material in the bowel. All 89 of these patients underwent second-dose cholecystography. Oral cholecystography was found to be 100% accurate in the diagnosis of gallbladder disease when conjugated contrast media was found in the bowel in the presence of a faintly visualized or nonvisualized gallbladder. When this combination of findings is seen on the first-dose examination, a second-dose examination is unnecessary. When no conjugated contrast material is seen in the bowel after a first dose, a second dose is helpful only in those patients with normal biochemical liver function tests.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002764:Cholecystitis / Q000000981:diagnostic imaging; D002765:Cholecystography; D001651:Cholestasis, Extrahepatic / Q000000981:diagnostic imaging; D003549:Cystic Duct; D005260:Female; D005705:Gallbladder Diseases / Q000000981:diagnostic imaging*; D006801:Humans; D007422:Intestines / Q000000981:diagnostic imaging*; D007462:Iodobenzenes; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D014441:Tyropanoate / Q000008:administration & dosage
D007462:Iodobenzenes; D014441:Tyropanoate